SecBot SecBot
EFFECT ·Filed Jul 10, 2026

NAGE

Niagen Bioscience, Inc.
BEARISH
Impact 6/10
Horizondays Processed3mo ago SEC9999999995-26-002240
IPO/offering going effective
Actionable Insight ▼ Bearish

The shelf is now live — management can execute the ATM at any time. Watch for prospectus supplements and actual share sales via Form 424B5 filings. Traders should monitor daily volume for distribution signs.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
NAGE ▼ -20.94% at T+60d
SHORT call ✓ call won +20.94% · α vs SPY +23.58% · entry $3.39 → $2.68
Entry = T+0 close
Jul 10, 2026
via day close
T+1d
+2.36%
call -2.36% · α -3.13%
$3.47
settled 4mo ago
T+5d
+0.29%
call -0.29% · α -0.86%
$3.40
settled 3mo ago
T+20d
-7.96%
call +7.96% · α +10.39%
$3.12
settled 3mo ago
T+60d
-20.94%
call +20.94% · α +23.58%
$2.68
settled 22d ago

Price Chart

Loading chart...

Executive Summary

The SEC declared effective Niagen Bioscience's S-3 shelf registration (File No. 333-297093) on July 9, 2026, clearing the way for the company to offer up to $125M in securities including an immediate $50M ATM program. This effectiveness removes the last procedural barrier to a large dilutive offering first disclosed 13 days ago, creating immediate overhang for common shareholders.

Key Facts

  • SEC effectiveness date: July 9, 2026
  • S-3 shelf registration covering up to $125M in securities
  • Includes $50M at-the-market (ATM) program through Canaccord Genuity and Roth Capital Partners
  • Current market cap: ~$268M — offering represents up to ~47% dilution if fully drawn
  • Net tangible book value disclosed at ~$76.8M in the prior S-3 filing
  • Company has history of negative net income and accumulated deficits

Financial Impact

Up to $125M in potential dilution — equivalent to ~47% of current $268M market cap. Immediate $50M ATM adds ~19% dilution at current prices.

dilutionshare countbook value per sharecommon equity

Risk Factors

  • Immediate ATM execution could dump shares into market, pressuring price
  • Full $125M drawdown would dilute existing holders by nearly 50%
  • Company's negative net income pattern suggests cash needs may force rapid drawdown

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002240
Document: 9999999995-26-002240-index.html9999999995-26-002240
Document: 9999999995-26-002240.txt9999999995-26-002240
6 reports for NAGE
Performance horizon
67% Hit rate @ T+60 2 of 3 directional calls Went positive at some point 2 of 3 best @ T+60▲ +22.48%Jul 10, 2026
Filters
Rows
Reports for NAGE — sortable, filterable
TypeNow
Jul 10, 2026
15w ago
424B5
BEARISH ★ 6/10
$3.47 $2.69▲ +22.48%▲ +26.47%$2.44 (+29.68%)
Jul 10, 2026
15w ago
EFFECT
BEARISH ★ 6/10
$3.39 $2.68▲ +20.94%▲ +23.58%$2.44 (+28.02%)
Jun 26, 2026
17w ago
S-3
BEARISH ★ 6/10
$3.30 $3.09▲ +6.36%▲ +10.75%$2.44 (+26.06%)
May 6, 2026
24w ago
8-K
MIXED ★ 5/10
$4.19 $3.53▼ −15.75%▼ −19.58%$2.44 (−41.77%)
Mar 4, 2026
33w ago
8-K
BULLISH ★ 7/10
$5.10 $3.61▼ −29.22%▼ −40.52%$2.44 (−52.16%)
Feb 26, 2026
34w ago
8-K
NEUTRAL ★ 5/10
$5.18 $3.79▼ −26.83%▼ −34.58%$2.44 (−52.90%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 10, 2026